|
1
|
Khosravi Shahi P and Fernández Pineda I:
Tumoral angiogenesis: Review of the literature. Cancer Invest.
26:104–108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Behera M, Pillai RN, Owonikoko TK, Kim S,
Steuer C, Chen Z, Saba NF, Belani CP, Khuri FR and Ramalingam SS:
Bevacizumab in combination with taxane versus non-taxane containing
regimens for advanced/metastatic nonsquamous non-small-cell lung
cancer: A systematic review. J Thorac Oncol. 10:1142–1147. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carnio S, Novello S, Mele T, Levra MG and
Scagliotti GV: Extending survival of stage IV non-small cell lung
cancer. Semin Oncol. 41:69–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du L and Morgensztern D: Chemotherapy for
Advanced-Stage Non-Small Cell Lung Cancer. Cancer J. 21:366–370.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cooper MR, Binkowski C, Hartung J and
Towle J: Profile of ramucirumab in the treatment of metastatic
non-small-cell lung cancer. Onco Targets Ther. 9:1953–1960. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shepherd FA, Crowley J, van Houtte P,
Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P;
International Association for the Study of Lung Cancer
International Staging Committee and Participating Institutions, :
The International Association for the Study of Lung Cancer lung
cancer staging project: Proposals regarding the clinical staging of
small cell lung cancer in the forthcoming (seventh) edition of the
tumor, node, metastasis classification for lung cancer. J Thorac
Oncol. 2:1067–1077. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pohl M and Schmiegel W: Therapeutic
Strategies in Diseases of the Digestive Tract-2015 and Beyond
Targeted Therapies in Colon Cancer Today and Tomorrow. Dig Dis.
34:574–579. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hanna N, Shepherd FA, Fossella FV, Pereira
JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M,
Muller T, et al: Randomized phase III trial of pemetrexed versus
docetaxel in patients with non-small-cell lung cancer previously
treated with chemotherapy. J Clin Oncol. 22:1589–1597. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garassino MC, Martelli O, Broggini M,
Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F,
Moscetti L, et al: Erlotinib versus docetaxel as second-line
treatment of patients with advanced non-small-cell lung cancer and
wild-type EGFR tumours (TAILOR): A randomised controlled trial.
Lancet Oncol. 14:981–988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katakami N, Atagi S, Goto K, Hida T, Horai
T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, et al:
LUX-Lung 4: A phase II trial of afatinib in patients with advanced
non-small-cell lung cancer who progressed during prior treatment
with erlotinib, gefitinib, or both. J Clin Oncol. 31:3335–3341.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adjei AA, Mandrekar SJ, Dy GK, Molina JR,
Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild
SE and Zinner RG: Phase II trial of pemetrexed plus bevacizumab for
second-line therapy of patients with advanced non-small-cell lung
cancer: NCCTG and SWOG study N0426. J Clin Oncol. 28:614–619. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Herbst RS, O'Neill VJ, Fehrenbacher L,
Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M and Sandler
A: Phase II study of efficacy and safety of bevacizumab in
combination with chemotherapy or erlotinib compared with
chemotherapy alone for treatment of recurrent or refractory
non-small-cell lung cancer. J Clin Oncol. 25:4743–4750. 2007.
View Article : Google Scholar : PubMed/NCBI
|
